^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

KRT5 (Keratin 5)

i
Other names: KRT5, Keratin 5, Keratin 5 (Epidermolysis Bullosa Simplex, Dowling-Meara/Kobner/Weber-Cockayne Types), Epidermolysis Bullosa Simplex 2 Dowling-Meara/Kobner/Weber-Cockayne Types, Keratin, Type II Cytoskeletal 5, Type-II Keratin Kb5, Keratin 5 Type II, Cytokeratin-5, KRT5A, CK-5, K5, 58 Kda Cytokeratin, 58 KDa Cytokeratin, Keratin-5, DDD1, EBS2, KRT5, CK5, DDD
10d
Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer-A Validation Study. (PubMed, Int J Mol Sci)
Nevertheless, our investigation revealed that the gene expression profiles failed to yield predictive value regarding the progression of early-stage NSCLC. Our molecular diagnostic models manifest the potential for an exhaustive molecular characterization of NSCLC, subsequently informing personalized treatment decisions and elevating the standards of clinical management and prognosis for patients.
Journal • Gene Signature
|
KRT5 (Keratin 5) • KRT6A (Keratin 6A) • MIR205 (MicroRNA 205)
14d
Prognostic Significance of the Cribriform Pattern in Prostate Cancer: Clinical Outcomes and Genomic Alterations. (PubMed, Cancers (Basel))
PC patients with CP4 have distinct genomic alterations and are at a high risk of disease progression following RP. Therefore, these patients may benefit from additional post-RP treatments and should be the subject of a prospective randomized clinical trial.
Clinical • Clinical data • Journal
|
KRT14 (Keratin 14) • TP63 (Tumor protein 63) • KRT5 (Keratin 5) • COL17A1 (Collagen Type XVII Alpha 1 Chain) • KRT16 (Keratin 16)
17d
Tissue Engineering Approaches to Treat COPD (clinicaltrials.gov)
P=N/A, N=30, Recruiting, University Hospitals of North Midlands NHS Trust | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
KRT5 (Keratin 5)
25d
Analysis of the types and functions of CD34+ cells in full-thickness skin defect wounds of normal mice and diabetic mice by single-cell RNA sequencing (PubMed, Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi)
CD34+ cells display high heterogeneity in the healing process of full-thickness skin defect wounds in both normal mice and diabetic mice. The significantly enriched functions of DEGs with SDE in CD34+ cell subpopulations in the wound tissue of the two mouse groups are closely related to the wound healing process.
Preclinical • Journal
|
CD74 (CD74 Molecule) • CD34 (CD34 molecule) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • KRT5 (Keratin 5) • FABP4 (Fatty Acid Binding Protein 4) • FMOD (Fibromodulin)
1m
The Effect of Retinoic Acid on Arsenite-Transformed Malignant UROtsa Bladder Cancer Cells: In Vitro Model of Basal Muscle-Invasive Bladder Cancer. (PubMed, Cancers (Basel))
Mechanistically, the antiproliferative effect of tretinoin was attributed to the downregulation of c-myc. Our results suggest that targeting the retinoic acid pathway can diminish the aggressive behavior of basal muscle-invasive urothelial cancer and may enhance patient survival.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5)
|
EGFR expression
2ms
Molecular subtyping and immunohistochemistry validation identifies muscle Invasive bladder cancer subgroups with poorer overall survival (AACR 2024)
Integrating MIBC subtyping, IHC of immune markers and patient outcomes data provides a biological framework that allows for potential biomarker identification for this lethal disease. The studies presented here underscore the existence of heterogeneity in immune phenotypes within tumor subtypes. A deeper understanding of the association between these tumor subtypes and their immunological states is crucial to guide treatment decisions, particularly for patients facing worse prognostic outcomes.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3) • KRT20 (Keratin 20) • KRT5 (Keratin 5)
|
VENTANA PD-L1 (SP263) Assay
2ms
Muc4 is a biomarker of metastasis in TNBC and its downregulation by blocking soluble TNF prevents metastasis in combination with immunotherapy (AACR 2024)
We have demonstrated that TNF induces trastuzumab resistance through mucin 4 (MUC4) upregulation and it is an independent biomarker of poor response to therapy in HER2+ breast cancer...TNF blockade was achieved with etanercept (E), which blocks the soluble (sTNF) and transmembrane isoform of TNF, or with the dominant negative protein INB03 (DN) which neutralizes only sTNF...MUC4 is associated with poorly-infiltrated TNBC, and sTNF blockade downregulates its expression decreasing MTS when combined with anti-PD-1. We propose the TNF as a new target for the treatment of TNBC, and MUC4 as a predictive biomarker to guide a combined treatment of TNF blockers with immunotherapy.
Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • AR (Androgen receptor) • MUC4 (Mucin 4, Cell Surface Associated) • KRT5 (Keratin 5)
|
MUC4 expression
|
VENTANA PD-L1 (SP142) Assay
|
Herceptin (trastuzumab) • INB03
2ms
Cytoplasmic expression of UTP23 promotes colorectal cancer progression. (PubMed, Cell Mol Biol (Noisy-le-grand))
Intriguingly, mass spectrometry result suggested that KRT5 bind to UTP23 and showed a regulatory influence on UTP23 metastatic potential in colorectal cancer cells. Conclusively, our study demonstrated that the localization of UTP23 play a key role in colorectal cancer metastatic progression, which may serve as a novel prognostic indicator.
Journal
|
KRT5 (Keratin 5)
2ms
New trial
|
KRT14 (Keratin 14) • TP63 (Tumor protein 63) • KRT5 (Keratin 5)
3ms
Journal
|
NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63) • KRT5 (Keratin 5) • NAPSA (Napsin A Aspartic Peptidase)
3ms
The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma. (PubMed, BMC Cancer)
The column line graphs created showed excellent discrimination and calibration to predict lymph node status in patients with ≤ 2 cm invasive lung adenocarcinoma. In addition, the predictive model has predictive potential before the end of surgery and can inform clinical decision making.
Journal
|
KRT5 (Keratin 5) • NAPSA (Napsin A Aspartic Peptidase)
3ms
Photobiomodulation Recovers the Submandibular Gland in Vismodegib-Treated Rats. (PubMed, Photobiomodul Photomed Laser Surg)
Also, 850 nm high-power LED recovered the damaged structure of SMG and increased SHH-related proteins and salivary functional markers. The study results suggest that PBM can restore SMG structure and function through SHH signaling.
Preclinical • Journal
|
PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1) • KRT5 (Keratin 5) • SHH (Sonic Hedgehog Signaling Molecule)
|
Erivedge (vismodegib)
3ms
Prenatal arsenic exposure alters keratinocyte stem cell fate through persistent activation of IGF2R-MAPK cascade leading to aggravated skin carcinogenesis in mice offspring. (PubMed, Mol Carcinog)
This was associated with reduced enrichment of histone H3K27me3 and its methylase, EZH2 along with increased binding of demethylase, KDM6A at Igf2r promoter. Altered KSCs conditioning through disturbed Igf2r imprint contributed to impaired proliferation and differentiation and an aggravated tumor response in offspring.
Preclinical • Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • BCL2L1 (BCL2-like 1) • KDM6A (Lysine Demethylase 6A) • CD34 (CD34 molecule) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen) • KRT5 (Keratin 5)
3ms
PD-L1 mRNA and protein expression in canine mammary carcinomas: Correlation with histopathological grade and molecular markers. (PubMed, Vet Pathol)
These findings suggest that PD-L1 expression in CMCs is heterogeneous and may be regulated post-transcriptionally. Further studies are needed to explore the prognostic and therapeutic implications of PD-L1 expression in different molecular subtypes of CMCs and their potential as predictive biomarkers for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • KRT5 (Keratin 5)
|
PD-L1 expression
3ms
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy. (PubMed, Front Oncol)
Post-NAC residual disease in TNBC showed biomarkers specific to a basal-like subtype and markers of lymphocyte infiltration mostly present in the stroma. Prognostic markers for EFS were AR, LVI, and ypN and warrant further validation in a prognostic model.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • AR (Androgen receptor) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3) • KRT5 (Keratin 5)
3ms
Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images. (PubMed, Int J Cancer)
By fusing the nuclei in H&E-stained images with MPM images, DCISM can be differentiated from suspicious small cancer clusters in DCIS. The proposed method demonstrated good consistency with the cytokeratin 5/6 (CK5/6) myoepithelial staining method (kappa coefficient = 0.818).
Journal
|
KRT5 (Keratin 5)
3ms
SOX4 reversibly induces phenotypic changes by suppressing the epithelial marker genes in human keratinocytes. (PubMed, Mol Biol Rep)
Our results indicate that SOX4 reversibly induces an EMT-like phenotype in human keratinocytes via suppression of epithelial marker genes.
Journal
|
CLDN1 (Claudin 1) • KRT5 (Keratin 5) • SOX4 (SRY-Box Transcription Factor 4)
3ms
Metastatic Pleomorphic Lobular Carcinoma of the Breast to the Urinary Bladder: A Report of 10 Cases and Assessment of TRPS1 in the Differential Diagnosis With Plasmacytoid Urothelial Carcinoma. (PubMed, Arch Pathol Lab Med)
Some PUCs express TRPS1. Caution should be exercised because immunophenotypes of these tumors greatly overlap, and ramifications of misclassification are major.
Journal • Metastases
|
ER (Estrogen receptor) • AR (Androgen receptor) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • TRPS1 (Transcriptional Repressor GATA Binding 1)
4ms
Increase of KLK7, cytokeratin 5/6, and elafin expression in head and neck squamous cell carcinoma compared with lung squamous cell carcinoma. (PubMed, J Histotechnol)
All three proteins were found to evidence higher expression in head and neck squamous cell carcinoma as compared with that of squamous cell carcinoma of the lung. The differences in expression may help clinical differentiation between primary tumors of the lung from metastatic tumors to the lung from the oral/laryngeal cavities.
Journal
|
KRT5 (Keratin 5) • KLK7 (Kallikrein Related Peptidase 7) • PI3 (Peptidase Inhibitor 3)
4ms
Malignant Para-Testicular Mesothelioma: A Rare Presentation in the Tunica Vaginalis of an Elderly Male With No Prior Asbestos Exposure. (PubMed, Int J Surg Pathol)
The differential diagnosis included adenomatoid tumors, germ cell tumors, and pleomorphic sarcoma. We aim to discuss the clinical presentation, diagnostic approach, and therapeutic approaches of this rare entity.
Journal
|
WT1 (WT1 Transcription Factor) • KRT5 (Keratin 5)
4ms
Establishment and Characterization of a TP53-Mutated Eyelid Sebaceous Carcinoma Cell Line. (PubMed, Invest Ophthalmol Vis Sci)
Cell proliferation assays were performed to identify sensitivity to mitomycin-C (MMC) and 5-fluorouracil (5-FU). The newly established eyelid SeC cell line SHNPH-SeC demonstrates mutation in TP53, the most commonly mutated gene in SeC. It presents SeC properties and malignant characteristics that may facilitate the investigation of cellular behaviors and molecular mechanisms of SeC to explore promising therapeutic strategies.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • KMT2C (Lysine Methyltransferase 2C) • KRT5 (Keratin 5) • PLIN2 (Perilipin)
|
TP53 mutation • HER-2 mutation
|
5-fluorouracil • mitomycin
5ms
CAV1 and KRT5 are potential targets for prostate cancer. (PubMed, Medicine (Baltimore))
CAV1 and KRT5 are highly expressed in prostate cancer. The higher expression of CAV1 and KRT5, the worse prognosis.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CAV1 (Caveolin 1) • KRT5 (Keratin 5) • PRKCA (Protein Kinase C Alpha) • SNAI2 (Snail Family Transcriptional Repressor 2) • DLG4 (Discs Large MAGUK Scaffold Protein 4)
|
FGFR1 expression • CAV1 expression
5ms
Clinicopathological analysis of bronchiolar adenoma combined with lung adenocarcinoma: Report of eight cases and literature review. (PubMed, Histol Histopathol)
There is no obvious boundary when BA and LUAD are in the same lesion. The luminal epithelial cells in the area where the two components migrate toward each other are atypical and lack a continuous underlying basal cell layer. Microscopic diagnosis should be aided by immunohistochemistry.
Review • Journal
|
NKX2-1 (NK2 Homeobox 1) • KRT5 (Keratin 5) • NAPSA (Napsin A Aspartic Peptidase)
|
TTF1 negative
5ms
Chemosensitivity of three patient-derived primary cultures of canine pericardial mesothelioma by single-agent and combination treatment. (PubMed, Front Vet Sci)
Lastly, chemosensitivity of established primary cultures against four drugs, doxorubicin, vinorelbine, carboplatin, and gemcitabine, by single-agent treatment as well as combination treatment of carboplatin at a fixed concentration, either 10 or 100 μM, and gemcitabine at different concentrations ranging from 0-1000 μM was assessed by cell viability assay. Primary cultures and xenograft models generated in this study could be useful tools for in vitro and in vivo studies of canine mesothelioma. Carboplatin is a highly effective chemotherapeutic agent against canine mesothelioma when used as a sole agent and in combination with gemcitabine.
Journal
|
WT1 (WT1 Transcription Factor) • VIM (Vimentin) • KRT5 (Keratin 5)
|
carboplatin • gemcitabine • doxorubicin hydrochloride • vinorelbine tartrate
5ms
Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy. (PubMed, Eur Urol Open Sci)
This method is cheaper and more widely available than the usual approach. However, we did not find an association between different cancer subtypes and survival.
Journal
|
GATA3 (GATA binding protein 3) • KRT5 (Keratin 5)
5ms
Multigene Profiling of Circulating Tumor Cells in Esophageal Squamous Cell Carcinoma Identifies Prognostic Cancer Driver Genes Associated with Epithelial-Mesenchymal-Transition Progression and Chemoresistance. (PubMed, Cancers (Basel))
High mRNA levels of TWIST1 (Hazard Ratio (HR) = 5.44, p = 0.007), VEGFC (HR = 6.67, p < 0.001), TFRC (HR = 2.63, p = 0.034), and EpCAM (HR = 2.53, p = 0.041) at baseline were significantly associated with a shorter overall survival (OS) in ESCC patients. This study also revealed that TWIST1 facilitates EMT and enhances malignant potential by promoting tumor migration, invasion, and cisplatin chemoresistance through the TWIST1-TGFBI-ZEB1 axis in ESCC, highlighting the prognostic and therapeutic potential of TWIST1 in clinical ESCC treatment.
Journal • Circulating tumor cells • Tumor cell
|
CCND1 (Cyclin D1) • EPCAM (Epithelial cell adhesion molecule) • VEGFC (Vascular Endothelial Growth Factor C) • TWIST1 (Twist Family BHLH Transcription Factor 1) • FSCN1 (Fascin Actin-Bundling Protein 1) • KRT5 (Keratin 5) • TGFBI (Transforming Growth Factor Beta Induced) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • KRT18 (Keratin 18)
|
cisplatin
5ms
Ruyong formula improves thymus function of CUMS-stimulated breast cancer mice. (PubMed, J Ethnopharmacol)
RYF could restore the structure and function of the thymus in depressed breast cancer mice by reversing the phenotypic changes of TECs and activating the JAK2/STAT3/PI3K pathway.
Preclinical • Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • IL7 (Interleukin 7) • KRT5 (Keratin 5) • TSLP (Thymic Stromal Lymphopoietin) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
6ms
Papillary cystadenoma of the major salivary gland: A case report and review of literature. (PubMed, Pathol Res Pract)
The patient is on close clinical and imaging follow-up for the last 1year and 8 months without any evidence of disease recurrence or metastasis. Rarity of the lesion and distinct histomorphology warrants appropriate knowledge and discussion of the subject.
Clinical • Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor) • NKX2-1 (NK2 Homeobox 1) • KRT7 (Keratin-7) • CDX2 (Caudal Type Homeobox 2) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • KRT20 (Keratin 20) • KRT5 (Keratin 5)
6ms
Target-Oriented Classification of Triple-negative Breast Cancer. (PubMed, Anticancer Res)
Almost all TNBC cases can be classified according to treatable targets.
Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • AR (Androgen receptor) • KRT5 (Keratin 5)
|
PD-L1 expression • HER-2 negative • HER-2 expression • PD-L1 negative • AR positive • PD-L1 expression + HER-2 overexpression
6ms
Metastatic triple negative breast cancer has distinct tumor immune landscape (SABCS 2023)
Our comprehensive biomarker analyses showed that metastatic TNBC has a more inflamed tumor microenvironment and higher checkpoint target expression compared to non-TNBC. Further analysis of immune expression by site-specific metastases and correlation with immunotherapy outcomes is warranted to guide clinicians in selection of the ideal metastatic site to biopsy for therapeutic decision making. However, in a collective TNBC context, these data support the use of immunotherapy in metastatic TNBC.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP3 (Lysosomal Associated Membrane Protein 3) • GZMB (Granzyme B) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • KRT5 (Keratin 5) • PRF1 (Perforin 1) • FCRLA (Fc Receptor Like A) • ITGA1 (Integrin Subunit Alpha 1)
|
HER-2 overexpression
|
PD-L1 IHC 22C3 pharmDx
6ms
Upregulation of the immune checkpoint protein B7-H3 is associated with an immune suppressive microenvironment in progression from in situ to invasive lobular breast cancer (SABCS 2023)
In sum, these strongly concurrent spatial transcriptome and protein data suggest that B7-H3 and the immune suppressive network of ILC may be a promising target for early stage lobular breast cancer. B7-H3 Inhibitors could be explored in the neoadjuvant setting to evaluate the efficacy of immunotherapy in primary ILC.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MMP2 (Matrix metallopeptidase 2) • CD27 (CD27 Molecule) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • KRT17 (Keratin 17) • FOXP3 (Forkhead Box P3) • KRT14 (Keratin 14) • CD40 (CD40 Molecule) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYLK (Myosin Light Chain Kinase) • POSTN (Periostin) • LUM (Lumican)
6ms
Clinico-Pathological and Molecular Characterization of Early Hormone Receptor-Positive Breast Cancer in Young Women (SABCS 2023)
However, further research is necessary to delve into the differential genomic characteristics that contribute to the unfavorable prognosis observed in patients diagnosed with HR+ EBC before the age of 40. Key clinical and molecular features in 441 biopsies
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BIRC5 (Baculoviral IAP repeat containing 5) • FOXA1 (Forkhead Box A1) • KRT17 (Keratin 17) • MELK (Maternal Embryonic Leucine Zipper Kinase) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CDC20 (Cell Division Cycle 20) • KRT5 (Keratin 5) • MYBL2 (MYB Proto-Oncogene Like 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative • ER expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
7ms
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab. (PubMed, Cancer Sci)
In conclusion, the improved outcomes of pembrolizumab treatment in mUC are restricted to patients with lower NLR. Our findings begin to elucidate a distinct molecular pattern for the presence of TLS according to the NLR in peripheral blood.
Journal • PD(L)-1 Biomarker
|
ICOSLG (Inducible T Cell Costimulator Ligand) • KRT17 (Keratin 17) • KRT5 (Keratin 5) • KRT18 (Keratin 18)
|
Keytruda (pembrolizumab)
7ms
Cutaneous carcinosarcoma, a true biphasic tumor or a phenomenon of divergent differentiation? – A rare case report (ASDP 2023)
 However, integrated cooperation across many medical specialties is often required for proper diagnosis. Poster type: Poster Defense
Clinical
|
KRT5 (Keratin 5)
7ms
Two cases of cutaneous sarcomatoid squamous cell carcinoma resembling cutaneous giant cell tumor of soft tissue (ASDP 2023)
Molecular analysis may also be helpful as H3F3 mutation or HMGA2-NCOR2 fusion would be evidence of GCT bone or GCT soft tissue rather than cSSCC. Poster type: Poster Defense
Clinical
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FAT1 (FAT atypical cadherin 1) • NCOR2 (Nuclear Receptor Corepressor 2) • CD68 (CD68 Molecule) • HMGA2 (High mobility group AT-hook 2) • SH2B3 (SH2B Adaptor Protein 3) • TP63 (Tumor protein 63) • KRT5 (Keratin 5)
7ms
Is there a “poorly differentiated” cutaneous basal cell carcinoma? (ASDP 2023)
Molecular analysis may help classify such tumors and show potential targetable mutations. Poster type: Poster Defense
Tumor mutational burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • TERT (Telomerase Reverse Transcriptase) • PTCH1 (Patched 1) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5)
|
TP53 mutation • TMB-H • PTCH1 mutation
8ms
PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases. (PubMed, J Clin Pathol)
Among the markers explored, only PAX5 and CD70 appear to be differentially expressed and are predominantly restricted to thymic carcinomas. Therefore, in small biopsy specimens and in resections in which the morphological features remain equivocal, application of these particular stains may facilitate separation of thymic carcinoma and atypical thymoma.
Journal
|
PAX5 (Paired Box 5) • CD70 (CD70 Molecule) • KRT5 (Keratin 5) • PAX2 (Paired Box 2) • PAX8 (Paired box 8)
|
CD70 expression